Xcout IntelMESOBLAST LTD competitors & alternatives
The 12 closest competitors and alternatives to MESOBLAST LTD among regenerative medicine companies — ranked by similarity to what MESOBLAST LTD actually does, not by market-cap band.
Subscribe to see MESOBLAST LTD’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About MESOBLAST LTD
Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company addresses a broad spectrum of medical conditions, including cardiovascular, spinal orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory diseases. At the core of its innovation is a proprietary regenerative medicine platform utilizing specialized mesenchymal lineage cells. Currently, several of Mesoblast's leading product candidates are undergoing Phase III clinical trials: remestemcel-L, designed for severe, steroid-refractory acute graft versus host disease and acute respiratory distress syndrome associated with COVID-19; Rexlemestrocel-L, aimed at advanced chronic heart failure; and MPC-06-ID, intended for chronic low back pain stemming from degenerative disc disease. Additionally, MPC-300-IV is being developed for biologic-refractory rheumatoid arthritis and diabetic nephropathy. The company has cultivated strategic partnerships to advance its pipeline and market reach. These collaborations include Tasly Pharmaceutical Group for the distribution of MPC-150-IM (heart failure) and MPC-25-IC (heart attacks) in China; JCR Pharmaceuticals Co. Ltd. for therapies addressing wound healing in patients with epidermolysis bullosa; and Grünenthal for the development and commercialization of cell therapy solutions for chronic low back pain. Mesoblast Limited was established in 2004 and maintains its headquarters in Melbourne, Australia.
MESOBLAST LTD at a glance
MESOBLAST LTD is a regenerative medicine company headquartered in Melbourne, Australia. It is publicly listed (MESO) with a market capitalisation of $1.8B. Xcout tracks 20 named people at MESOBLAST LTD, including Paul J. Simmons (Scientific Advisor to the Chief Executive Officer).
MESOBLAST LTD leadership
- Paul J. SimmonsScientific Advisor to the Chief Executive Officer
- James Michael O'BrienChief Financial Officer
- Eric A. RoseChief Medical Officer & Executive Director
- Marcelo SantoroChief Commercial Officer
- Silviu Itescu FACP FACRA FRACP MBBSFounder, Chief Executive Officer, MD, Chairman of Scientific Advisory Board & Executive Director
- Fiona SeeSenior Vice President & Head of Translational Research
14 more named people on record for MESOBLAST LTD, with roles, board committees and tenure — see the full roster →
Top 12 MESOBLAST LTD competitors
Ranked by semantic similarity — how close each company is to MESOBLAST LTD by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biopharmaceuticals
Mabpharm Limited is a Chinese biopharmaceutical firm dedicated to the research, development, and manufacturing of innovative and biosimilar medications. Its therapeutic focus areas include allergic conditions, various cancers, and autoimmune disorders. The company boasts a robust pipeline, with several key products currently in advanced Phase III clinical trials. These include CMAB007, a recombinant humanized anti-IgE monoclonal antibody targeting asthma; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the initial treatment of metastatic colorectal cancer; CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody designed for moderate to severe active rheumatoid arthritis; and CMAB807, an agent developed for osteoporosis. Furthermore, Mabpharm is progressing various candidates through Phase I clinical development. Among these are CMAB819, aimed at treating metastatic non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinomas; CMAB807X, formulated for tumor bone metastasis; and CMAB809, which targets HER2 overexpressing breast cancer and metastatic gastric cancer. The preclinical pipeline is equally extensive, featuring CMAB810 for breast cancer; CMAB816, addressing periodic fever syndrome, lung cancer, and systemic juvenile idiopathic arthritis; and CMAB017, intended for KRAS wild-type colorectal cancer. Also in preclinical stages are biosimilar candidates such as CMAB015, an analog of secukinumab for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis; CMAB018, a mepolizumab biosimilar for asthma and eosinophilic granulomatous polyangiitis; and CMAB022, designed for various inflammatory conditions. Beyond its product development, Mabpharm provides a range of related services, including contract research and development, technical consultation, technology transfer, and specialized technical support for biological products, diagnostic and chemical biological reagents, and pharmaceutical compounds. Established in 2018, Mabpharm Limited is headquartered in Taizhou, People's Republic of China.
Gene Therapy
Mirugen Pty Ltd is a preclinical biotechnology company founded in 2022 and headquartered in Melbourne, Australia, dedicated to reprogramming cells to unlock innate cellular functions.
Materials
First Graphene Limited, an Australian enterprise, is actively engaged in the comprehensive lifecycle of graphene products, from initial research, development, and mining to their manufacture and global distribution. The company organizes its operations across three key divisions: Graphene Production, Research and Development, and Mining Asset Maintenance. Its product line, marketed under the PureGRAPH brand, encompasses a range of graphene-enhanced offerings, including MB-LDPE and MB-EVA masterbatches (with a specialized bitumen variant), pre-dispersed aqua graphene additives, and nanoplatelet additives. Beyond these, First Graphene also innovates and commercializes VFD, TTF, and other advanced 2D devices and materials. These versatile solutions find application across numerous sectors such as coatings and inks, composites, elastomers, fire retardancy, concrete, textiles, and energy storage. The company's principal office is situated in Henderson, Australia.
Biopharmaceutical
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
Household & Personal Products
Biome Australia Limited, founded in 2018 and headquartered in Cremorne, Australia, specializes in the development, commercialization, and global distribution of live biotherapeutic and complementary health products. The company's product line features live biotherapeutics under the Activated Probiotics brand, organic nutritional supplements branded as Activated Nutrients, and athletic performance and recovery items named Activated X Performance. These offerings are accessible to consumers through both community pharmacies and independent health practitioners.
Household & Personal Products
Holista CollTech Limited is a biotechnology firm with operations spanning Australia, Malaysia, and the United States. Its business activities are organized into four key divisions: Supplements, Ovine Collagen, Infection Control Solutions, and Food Ingredients. The company specializes in the production and distribution of dietary supplements, cosmetic-quality collagen, and a variety of health-conscious food ingredients. These innovative food products include low-glycemic index (GI) flour blends suitable for noodles, pasta, flatbreads, and other baked goods, along with low-sodium salt, reduced-fat fried options, and both less-calorie and low-GI sugar alternatives. Furthermore, Holista CollTech offers solutions for infection control. Its corporate headquarters are located in Subiaco, Australia.
Battery Technology
Ilika plc, an enterprise established in 2004 with its headquarters in Romsey, United Kingdom, focuses on the conception, refinement, and commercial production of solid-state battery technology. These advanced power cells are distributed globally under their Stereax brand, primarily serving markets in the UK, Asia, mainland Europe, and North America. The company's battery solutions find application across numerous sectors, such as industrial Internet of Things, medical apparatus, various transportation systems including electric vehicles, and portable consumer electronics, as well as supporting smart city initiatives.
Similar regenerative medicine company
CCRM Enterprises Holdings Ltd. acts as a catalyst for commercializing regenerative medicines and cell and gene therapies. The organization bridges academia and industry by providing stakeholders, expertise, specialized infrastructure, and funding to accelerate product development and launch companies.
Biopharmaceuticals
CAGE Bio is a clinical-stage biotechnology company that develops localized therapies for dermatology, inflammation, and immunology. The company utilizes a proprietary deep eutectic ionic liquid platform to enable the skin penetration of small and large molecules, providing topical treatments designed to avoid the side effects of systemic drug exposure.
Drug Discovery
Versameb AG is a privately held biopharmaceutical company focused on discovering and developing innovative RNA-based therapeutics.
Biopharmaceuticals
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.
Biopharmaceuticals
CSL Behring is a global biotechnology company that develops and provides plasma-derived and recombinant therapies. Through its divisions, the company delivers treatments for rare and serious diseases, influenza vaccines, iron deficiency, and nephrology conditions to patients worldwide.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of MESOBLAST LTD and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for MESOBLAST LTDand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →